Coexpression of p-IGF-1R and MMP-7 modulates panitumumab and cetuximab efficacy in RAS Wild-Type metastatic colorectal cancer patients
MetadataShow full item record
INTRODUCTION: The coexpression of pIGF-1R and MMP-7 (double-positive phenotype, DP) correlates with poor overall survival (OS) in KRAS wild-type (WT) (exon 2) metastatic colorectal cancer (mCRC) patients treated with irinotecan-cetuximab in second/third line. METHODS: We analyzed two prospective biomarker
design trials of newly diagnosed RAS-WT mCRC patients treated with panitumumab-FOLFOX6 (PULSE trial; NCT01288339) or cetuximab plus either FOLFOX6/FOLFIRI (POSIBA trial; NCT01276379). The main exposure was DP phenotype (DP/non-DP), as assessed by two independent pathologists. DP cases were defined by immunohistochemistry as >70% expression of moderate or strong intensity for both MMP-7 and pIGF-1R. Primary endpoint: progression-free survival (PFS); secondary endpoints: OS and response rate. PFS and OS were adjusted by baseline characteristics using multivariate Cox models. RESULTS: We analyzed 67 patients (30 non-DP, 37 DP) in the PULSE trial and 181 patients in the POSIBA trial (158 non-DP, 23 DP). Response rates and PFS were similar between groups in both studies. DP was associated with prolonged OS in PULSE (adjusted HR: 0.23; 95%CI: 0.11-0.52; P=.0004) and with shorter OS in POSIBA (adjusted HR: 1.67; 95%CI: 0.96-2.90; P=.07). CONCLUSION: A differential effect of anti-EGFRs on survival by DP phenotype was observed. Panitumumab might be more beneficial for RAS-WT mCRC patients with DP phenotype, whereas cetuximab might improve OS in non-DP.
Is part ofNeoplasia, 2018, vol. 20, núm. 7, p. 678–686
European research projects
The following license files are associated with this item:
Except where otherwise noted, this item's license is described as cc-by-nc-nd (c) Alonso et al., 2018
Showing items related by title, author, creator and subject.
Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer Feliu, Jaume; Safont, M. J.; Salud Salvia, Maria Antonieta; Losa, F.; García-Girón, C.; Bosch, Carlos; Escudero, P.; López, R.; Madroñal, C.; Bolaños, M.; Gil, M.; Llombart, A.; Castro-Carpeño, J.; González-Barón, M. (Nature Publishing GroupCancer Research UK, 2010)BACKGROUND: The efficacy and safety of capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer (mCRC) considered unsuitable for receiving first-line chemotherapy with an irinotecan or oxaliplatin-based ...
Correlation of hypertension and proteinuria with outcome in elderly bevacizumab treated patients with metastatic colorectal cancer Feliu, Jaume; Salud Salvia, Maria Antonieta; Safont, M. J.; García-Girón, C.; Aparicio, Jorge; Losa, F.; Bosch, Carlos; Escudero, P.; Casado, Enrique; Jorge, Monica; Bohn, Uriel; Pérez-Carrión, Ramon; Carmona, Alberto; Custodio, Ana B.; Maurel, Joan (Public Library of Science, 2015)Background Studies suggest a relationship between hypertension and outcome in bevacizumab-treated patients with metastatic colorectal cancer (mCRC). We performed a retrospective analysis of two phase II studies (BECA ...
First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study Feliu, Jaume; Salud Salvia, Maria Antonieta; Safont, M. J.; García-Girón, C.; Aparicio, Jorge; Serra, O.; Vera, R.; Casado, Enrique; Jorge, Monica; Escudero, P.; Bosch, Carlos; Bohn, Uriel; Pérez-Carrión, Ramon; Carmona, Alberto; Martínez-Marín, V.; Maurel, Joan (Cancer Research UK, 2014)Background: Subgroup analyses of clinical studies suggest that bevacizumab plus XELOX is effective and tolerable in elderly patients with metastatic colorectal cancer (mCRC). The prospective BECOX study examined the ...